Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Nomlabofusp · CTI-1601

Fusion protein · Protein replacement · developed by Larimar Therapeutics

Phase 3 Most advanced trial
LRMR Developer
2 Registered trials

What is Nomlabofusp?

Nomlabofusp (CTI-1601) is a recombinant fusion protein designed to deliver human frataxin, the protein deficient in Friedreich's ataxia. It is given by subcutaneous injection and is studied in Friedreich's ataxia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CTI-1601
Drug type
Fusion protein
Mechanism
Protein replacement
Therapy area
Neurology
Developer
Larimar Therapeutics, Inc. (LRMR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
V6S49GL5GS

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07778836 Phase 3 Friedreich Ataxia Recruiting LRMR
NCT06447025 Phase 2 Friedreich Ataxia Recruiting LRMR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Friedreich AtaxiaFriedreich's Ataxia

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LRMR page.

Follow LRMR, the company behind Nomlabofusp

See LRMR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LRMR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.